The Technical Analyst
Aurinia Pharmaceuticals [AUPH]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aurinia Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.24% $4.80
America/New_York / 18 apr 2024 @ 13:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 694.17 mill |
| EPS: | -0.540 |
| P/E: | -8.89 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 144.62 mill |
| Avg Daily Volume: | 2.11 mill |
| RATING 2024-04-18 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.89 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.51x |
| Company: PE -8.89 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.58 - 5.03 ( +/- 4.69%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Greenleaf Peter | Sell | 126 981 | Common Stock |
| 2024-03-06 | Miller Joseph M | Sell | 34 811 | Common Stock |
| 2024-03-06 | Donley Matthew Maxwell | Sell | 40 665 | Common Stock |
| 2024-03-06 | Habig Scott Michael | Sell | 17 777 | Common Stock |
| 2024-03-06 | Robertson Stephen P. | Sell | 57 745 | Common Stock |
| INSIDER POWER |
|---|
| 72.46 |
| Last 95 transactions |
| Buy: 5 896 445 | Sell: 560 044 |
Forecast:
15:08 - $4.80
Live Trading Signals (every 1 min)
Forecast
1: 13:38 - $4.79
Forecast 2: 14:28 - $4.81
Forecast 3: 15:08 - $4.80
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.80 (-2.24% ) |
| Volume | 0.913 mill |
| Avg. Vol. | 2.11 mill |
| % of Avg. Vol | 43.20 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AUPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $7.90 | N/A | Active |
|---|
AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Latest Press Releases
2024-04-16 10:48:00 - Press Release
Update: New Aurinia Presentation Details At The 2024 Bloom Burton & Co. Healthcare Investor Conference
Rockville, md. & edmonton, alberta--(business wire)--update: new aurinia presentation details at the 2024 bloom burton & co. healthcare investor conference.
2024-04-15 06:00:00 - Press Release
Aurinia Pharmaceuticals To Release First Quarter Financial And Operational Results On May 2, 2024
Rockville, md. & edmonton, alberta--(business wire)--aurinia pharmaceuticals to release first quarter financial and operational results on may 2, 2024.
2024-04-09 06:00:00 - Press Release
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
Rockville, md. & edmonton, alberta--(business wire)--aurinia will attend 2024 bloom burton & co. healthcare investor conference.
2024-02-29 08:30:00 - Press Release
Aurinia Receives Exemptive Relief From Canadian Securities Regulators For Share Repurchase Program
Rockville, md. & edmonton, alberta--(business wire)--aurinia receives exemptive relief from canadian securities regulators for share repurchase program.
2024-02-27 08:30:00 - Press Release
Aurinia To Participate In Upcoming Investor Healthcare Conferences
Rockville, md. & edmonton, alberta--(business wire)--aurinia to participate in upcoming investor healthcare conferences.
Latest News
2024-04-16 10:48:00 - Business Wire
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference.
2024-04-15 06:00:00 - Business Wire
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024.
2024-04-09 06:00:00 - Business Wire
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference.
2024-02-15 08:26:04 - Zacks Investment Research
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago.
2024-02-15 05:22:01 - Reuters
Exclusive: Kidney drug developer Aurinia fails to clinch a sale, sources say
Aurinia Pharmaceuticals , the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to attract binding offers and will embark on share buybacks and cost cuts instead, people familiar with the matter said.
2024-02-08 11:05:55 - Zacks Investment Research
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-05 08:30:00 - Business Wire
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024.
2023-12-28 11:18:09 - Zacks Investment Research
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
2023-12-11 12:02:11 - Zacks Investment Research
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
2023-11-20 11:18:23 - Zacks Investment Research
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
Here is how Aurinia Pharmaceuticals (AUPH) and Adma Biologics (ADMA) have performed compared to their sector so far this year.